T

TG Therapeutics

D
TGTX
USD
0.05
(0.1981%)
Market Closed
190,928.00
Volume
0.37
EPS
-
Div Yield
37.176
P/E
3,915,477,134.73
Market Cap
Today
0.1981%
1 Week
9.103%
1 Month
0.437%
6 Months
64.971%
12 Months
163.987%
Year To Date
48.155%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
GILD
GILD
0.015
(0.0179%)
USD
I
INCY
1.67
(2.5625%)
USD
K
KPTI
-0.0002
(-0.027%)
USD
A
ARRY
-0.21
(-3.0792%)
USD
P
PRTA
0.18
(0.8372%)
USD
C
CRVS
0.07
(1.275%)
USD
NVS
NVS
-0.02
(-0.0172%)
USD
BMY
BMY
-0.72
(-1.4475%)
USD
GSK
GSK
-0.78
(-1.8383%)
USD
AZN
AZN
0.32
(0.4072%)
USD

Title:
TG Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Do you need help or have a question?
Contact Us